Stockscreener 앱 받기
15.04
0.33%
-0.05
시간 외 거래:
14.91
-0.13
-0.86%
전일 마감가:
$15.09
열려 있는:
$15.18
하루 거래량:
11.80M
Relative Volume:
1.75
시가총액:
$10.27B
수익:
$125.68M
순이익/손실:
$4.81B
주가수익비율:
2.6619
EPS:
5.65
순현금흐름:
$-781.21M
1주 성능:
+6.82%
1개월 성능:
+27.89%
6개월 성능:
+37.48%
1년 성능:
+26.17%
1일 변동 폭
$14.81
$15.18
1주일 범위
$13.81
$16.05
52주 변동 폭
$8.73
$16.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
명칭
Roivant Sciences Ltd
전화
441-295-5950
주소
7TH FLOOR, 50 BROADWAY, LONDON
ROIV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
15.04 | 10.30B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-02 | 개시 | Citigroup | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-01-05 | 개시 | Piper Sandler | Overweight |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-17 | 개시 | Guggenheim | Buy |
| 2023-06-08 | 개시 | BofA Securities | Neutral |
| 2022-10-27 | 개시 | JP Morgan | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 개시 | Goldman | Buy |
| 2021-11-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-28 | 개시 | Citigroup | Buy |
| 2021-10-26 | 개시 | Cowen | Outperform |
| 2021-10-26 | 개시 | Jefferies | Buy |
| 2021-10-26 | 개시 | Truist | Buy |
모두보기
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
Roivant Sciences Hits Day High with Strong 7.76% Intraday Surge - Markets Mojo
Ramaswamy Sells $23 Million of Roivant Sciences Stock -- Barron's - 富途牛牛
Matthew Gline Purchases 3,315 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Peak Financial Advisors LLC Acquires Shares of 41,880 Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $24.00 - MarketBeat
Stock Report: Should you buy the dip on Allakos IncJuly 2025 Momentum & Fast Gain Swing Trade Alerts - khodrobank.com
Aug Spikes: Is Roivant Sciences Ltd stock risky to hold nowTrade Volume Report & AI Powered Trade Plan Recommendations - khodrobank.com
Roivant Sciences (NASDAQ:ROIV) Given New $20.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $22.00 at Leerink Partners - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Given New $16.50 Price Target at Bank of America - MarketBeat
Why Roivant Sciences Stock Is Soaring Today - Mitrade
HC Wainwright Issues Positive Forecast for Roivant Sciences (NASDAQ:ROIV) Stock Price - MarketBeat
29,982 Shares in Roivant Sciences Ltd. $ROIV Purchased by Inspire Investing LLC - MarketBeat
Roivant Sciences CEO Gline buys $49,957 in shares By Investing.com - Investing.com Australia
Insider Buying: Matthew Gline Acquires Shares of Roivant Sciences Ltd (ROIV) - GuruFocus
Roivant Sciences Hits New 52-Week High of $16.05, Up 44.42% - Markets Mojo
Fed Watch: Is Roivant Sciences Ltd benefiting from innovation trendsJuly 2025 Closing Moves & Advanced Technical Signal Analysis - khodrobank.com
Roivant Sciences CEO Gline buys $49,957 in shares - Investing.com
Goldman Sachs Raises Roivant Sciences (ROIV) Price Target to $24 | ROIV Stock News - GuruFocus
Jefferies Raises Price Target for ROIV to $20, Maintains Buy Rat - GuruFocus
Roivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive Results - Yahoo
JP Morgan Raises Price Target for Roivant Sciences (ROIV) to $20 - GuruFocus
Roivant Sciences (NASDAQ:ROIV) Reaches New 12-Month HighShould You Buy? - MarketBeat
Roivant Sciences stock price target raised to $20 by H.C. Wainwright - Investing.com South Africa
ROIV: Leerink Partners Raises Price Target to $22 Following Outp - GuruFocus
ROIV Stock: Guggenheim Raises Price Target to $21.00, Maintains - GuruFocus
Roivant Sciences (ROIV) Sees Price Target Raised by B of A Securities | ROIV Stock News - GuruFocus
Big Money Moves: Can Roivant Sciences Ltd. scale operations efficientlyMarket Volume Summary & AI Forecast for Swing Trade Picks - khodrobank.com
Analyst Raises Price Target for Roivant Sciences (ROIV) | ROIV S - GuruFocus
Roivant: Brepocitinib’s DM Data Impress, Pipeline Focus Narrows (NASDAQ:ROIV) - Seeking Alpha
Dow Update: Can Roivant Sciences Ltd. ride the EV wave2025 Sector Review & Verified Stock Trade Ideas - خودرو بانک
Bull Bear: Will GP Act III Acquisition Corp. face regulatory challenges2025 Trading Volume Trends & Community Driven Trade Alerts - khodrobank.com
Roivant Stock Surges on Positive Phase 3 Dermatomyositis Trial - NAI500
Roivant Sciences stock price target raised to $24 by Goldman Sachs - Investing.com Canada
Roivant Sets The Stage For Commercial Return With Brepocitinib Data - insights.citeline.com
Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease TrialRoivant Sciences (NASDAQ:ROIV) - Benzinga
Risk Off: What is Citizens Funding Trust I Preferred Securitys TAM Total Addressable MarketEarnings Growth Report & Real-Time Volume Surge Alerts - خودرو بانک
Roivant, Priovant plan NDA on positive dermatomyositis data - BioWorld MedTech
Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday - Benzinga
Roivant and Priovant announce positive phase 3 Valor study results for brepocitinib in 52-week placebo-controlled trial in dermatomyositis (Dm) - MarketScreener
Roivant (ROIV) Reports Positive Phase 3 Results for Brepocitinib - GuruFocus
Why Roivant Sciences Shares Could See a Boost - TipRanks
Roivant stock surges after positive Phase 3 trial results for dermatomyositis - Investing.com Australia
Roivant Sciences : Brepo VALOR TLR vFF - MarketScreener
Roivant and Pfizer-backed Priovant post late-stage trial win for dermatomyositis therapy - Seeking Alpha
Roivant stock surges after positive Phase 3 trial results for dermatomyositis By Investing.com - Investing.com South Africa
Roivant, Priovant Say Dermatomyositis Treatment Meets Main Goal in Phase 3 Study; Shares up Pre-Bell - MarketScreener
S&P 500 Futures Steady in Premarket Trading; Workday, Roivant Sciences Lead - Barron's
Pharma News: Will Roivant Sciences Ltd benefit from sector rotation2025 Breakouts & Breakdowns & Weekly Top Gainers Alerts - khodrobank.com
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) - MarketScreener
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) - GlobeNewswire Inc.
Roivant Sciences Ltd (ROIV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.43%
0.09%
자본화:
|
볼륨(24시간):